Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 2/20 | 0.43 |
| ▸ | GABRD | O14764 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465796 | 1.00 | KMT2A (0.46) | KMT2AKDM4EMEN1ALDH1A1TDP1 | |
| SCHEMBL20331043 | 0.84 | SIRT6 (0.47) | NAPRTSIRT6LMNASMN1; SMN2 | |
| SCHEMBL7813902 | 0.84 | GABRP (0.47) | KMT2AKDM4EMEN1ALDH1A1TDP1 | |
| SCHEMBL30292600 | 0.82 | SIRT6 (0.37) | KMT2AKDM4EMEN1ALDH1A1TDP1 | |
| SCHEMBL2185131 | 0.82 | SIRT6 (0.37) | KMT2AKDM4EMEN1ALDH1A1TDP1 | |
| SCHEMBL29773884 | 0.81 | NAPRT (0.47) | KMT2AKDM4EALDH1A1CYP3A4GABRP | |
| SCHEMBL979398 | 0.81 | NAPRT (0.47) | KMT2AKDM4EALDH1A1CYP3A4GABRP | |
| SCHEMBL4849794 | 0.80 | MAPT (0.53) | KMT2AMEN1ALDH1A1TDP1MAPT | |
| SCHEMBL29411268 | 0.79 | ALDH1A1 (0.47) | KMT2AKDM4EMEN1ALDH1A1TDP1 | |
| SCHEMBL1300053 | 0.79 | ALDH1A1 (0.47) | KMT2AKDM4EMEN1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720061-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720062-A1 | PYRIDO[3,4-D]PYRIMIDIN-4-ONE AND PYRIMIDO[5,4-D]PYRIMIDIN-4-ONE DERIVATIVES AS TREM2 AGONISTS FOR THE TREATMENT OF PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12565511-B2 | SOS1 inhibitor containing phosphorus | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-03-03 | — | — | US | disclosed |
| US-20260035375-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2026-02-05 | — | — | US | disclosed |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2026-01-08 | — | — | US | disclosed |
| EP-4674415-A2 | AZAQUINOLINES AS INHIBITORS OF CD38 | Boehringer Ingelheim International GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025202022-A9 | ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-26 | — | — | WO | disclosed |
| US-6455534-B2 | ANTIPROLIVERATIVE, -CARCINOGENIC AND -TUMOR AGENTS; MITOGENESIS-ACTIVATED PROTEIN KINASE INHIBITORS; NONCYTOTOXIC; BINDING WITH HIGH AFFINITY AT THE ADENOSINE TRIPHOSPHATE BINDING SITE OF THE KINASES | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2001-10-04 | — | — | US | disclosed |
| US-6265410-B1 | ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6084095-A | INCLUDING 6-AMINO-4-(3-BROMOANILINO)PYRIDO(3,2-D)PYRIMIDINE; 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO (3,2-D)PYRIMIDINE; AND 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO(3,2-D)PYRIMIDINE; USEFUL IN TREATING PROLIFERATIVE DISEASES SUCH AS CANCER | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5654307-A | ANTICARCINOGENIC AGENTS, ANTIARTHRITIC AGENT, SKIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| CN-1139383-A | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | WARNER LAMBERT CO (US) | 1997-01-01 | — | — | CN | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
| US-3962264-A | AMMONIA, TETRA-ALKOXY-PROPANE, MALONONITRILE | PFIZER INC. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3950160-A | INHIBITING THE GROWTH OF WEEDS WITH 2-SUBSTITUTED PYRDIDOPYIMIDINES AND SALTS THEREOF | PFIZER INC. (US) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | CBL, CBLC, CBLB | KMT2A 2417/4885KDM4E 2543/4885MEN1 4166/4885 |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | KMT2A 1917/4885KDM4E 1396/4885MEN1 3319/4885 |
| US-12565511-B2 | SOS1 inhibitor containing phosphorus | SOST, SOS1, SOS2 | KMT2A 4626/4885KDM4E 4495/4885MEN1 438/4885 |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SOS1, OPRL1, SOS2 | KMT2A 4483/4885KDM4E 4190/4885MEN1 2585/4885 |
| US-20260035375-A1 | TREM2 MODULATORS | MSR1, CSF1R, CX3CR1 | KMT2A 1995/4885KDM4E 3013/4885MEN1 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.